Aureka has completed a $100M Series B financing, just 4 months after its last round. The company builds a dry-wet lab loop infrastructure using AI to design antibodies and other large molecule drugs. Its open-source engine OpenDDE outperforms AlphaFold3 in antibody-antigen prediction. With 8 public pipelines, 1 candidate is entering clinical and 2 are in IND development.









